Substipharm is a privately held pharmaceutical Group. We develop, supply and commercialize pharmaceuticals in more than 90 countries worldwide. Our portfolio of products that we currently license out or distribute directly or through partners comprises more than 90 different molecules. Our development pipeline includes as well more than 50 ongoing projects. We have a successful portfolio of pharmaceutical products and vaccines including: Mature brands Generics Over the counter (OTC) pharmaceuticals Difficult to develop medicines Value added presentations Biological products including vaccines:
| Website | http://www.substipharm.com |
| Revenue | $5.4 million |
| Employees | 157 (96 on RocketReach) |
| Founded | 1995 |
| Address | 24, Rue Erlanger, Paris, Île-de-France 75016, FR |
| Phone | +1 301-816-2424 |
| Industry | Pharmaceutical Manufacturing |
| Competitors | Amgen, Teva Pharmaceuticals, Sandoz, Viatris, Fresenius Kabi, Hikma Pharmaceuticals, Purdue Pharma L.P., Sunkist Growers, Lannett Company, Inc., Accord Healthcare Greece +40 more (view full list) |
Looking for a particular Substipharm employee's phone or email?
The Substipharm annual revenue was $5.4 million in 2026.
Cédric Ripert is the Chief Commercial Officer (CCO) of Substipharm.
96 people are employed at Substipharm.
Substipharm is based in Paris, Île-de-France.